A poorly adapted PRO (Patient-Reported Outcome) questionnaire can distort the primary endpoint of an entire clinical trial. If a pain scale or quality-of-life measure does not capture the same concept in Portuguese as in the English original, data collected in Lisbon or São Paulo stops being comparable with other trial sites. This is why regulators such as the EMA and the FDA require a documented linguistic validation process, not a straightforward translation.
What sets linguistic validation apart from standard translation
A PRO instrument measures subjective concepts such as pain, fatigue or emotional functioning through items whose wording has been statistically tested in the source language. Translating those items word for word does not guarantee that a Portuguese or Brazilian patient will interpret the question the same way as a patient in the original study population.
Linguistic validation follows a defined methodology, typically based on ISPOR (International Society for Pharmacoeconomics and Outcomes Research) principles:
- Forward translation by two independent translators working separately
- Reconciliation of both versions into a single agreed translation
- Back translation into the source language, carried out by a third translator who has never seen the original text
- Comparison between the back translation and the source document by the instrument's copyright holder, usually the organisation that developed the scale
- Cognitive debriefing with a small group of real patients, to confirm each item is understood as intended
- Harmonisation across all language versions used in a multicentre study
This process can take weeks, not days, precisely because it involves several review rounds with the instrument's copyright holder and, in some cases, with ethics committees.
Why cognitive debriefing is the step most often skipped
Many sponsors treat cognitive debriefing as optional when deadlines tighten. That is a costly mistake. An anxiety scale that uses an English idiom might be translated with perfect grammar and still confuse a 70-year-old patient in Portugal, who reads the question literally and answers something that does not match the original item's intent.
Cognitive debriefing involves interviewing five to eight patients from the target population, matched by age range and clinical condition, and asking them to explain each question in their own words. Discrepancies at this stage require rewording before final harmonisation. Without this step, a CRO typically only discovers the problem once data has already been collected, when one country's outlier values stand out in the statistical analysis.
Documentation regulators expect to see
The EMA and the FDA expect submission dossiers to include evidence that the linguistic validation process was followed and documented at every stage. This typically includes:
- A translation report identifying the translators and their qualifications
- A log of all discrepancies found during reconciliation and how they were resolved
- A cognitive debriefing report, with patient responses and any resulting wording changes
- A linguistic harmonisation certificate when the study runs across several countries
- Final sign-off from the PRO instrument's copyright holder
This documentation needs to align with the translation of the clinical trial protocol itself, which defines the population, endpoints and inclusion criteria the PRO instrument is tied to. Terminology inconsistencies between the protocol and the PRO instrument are a common reason regulators send back requests for clarification.
Common mistakes that delay approval
The most frequent problems are not grammar errors. They are conceptual equivalence failures:
- Translating a frequency scale ("always", "sometimes", "never") without checking whether the adverbs carry the same perceived weight in the target language
- Using clinical terminology instead of lay language, when the original instrument was designed to be understood by a patient with no medical training
- Overlooking cultural differences in how pain or emotional distress is expressed, which vary significantly even across countries that share a language
- Reusing a previously validated translation for a new study without confirming that the target population and clinical context are equivalent
When the same questionnaire is used in UK English and US English, harmonisation still needs care. The same word can carry different connotations in each market, and treating regional variants as interchangeable is a recurring mistake in multicentre studies.
How M21Global supports this process
M21Global works to ISO 17100 certified standards for pharmaceutical translation, which supports the forward translation, reconciliation and back translation workflows that PRO linguistic validation requires. For this type of project, the Estratégica tier provides review by a second linguist and the documentation trail that regulators such as the EMA expect to see.
If the trial also requires translation of labelling or medical device documentation under the MDR, coordinating both workflows with the same linguistic partner keeps terminology consistent between the PRO instrument and the rest of the dossier. Visit the pharmaceutical translation page to see how this process fits into the wider clinical trial documentation.
Related Services
Request a free medical translation quote
- Request a free medical translation quote
- Medical Device Documentation Translation Mdr Compliance
- Translating Clinical Trial Protocols Regulatory Submission
- Drug Labeling Translation
Frequently Asked Questions
What is a PRO questionnaire in clinical trials?
A Patient-Reported Outcome instrument directly records a patient's perception of symptoms, quality of life or treatment effect, without interpretation by a clinician.
What is the difference between translation and linguistic validation of a PRO?
Translation converts the text into another language. Linguistic validation adds back translation, cognitive debriefing with real patients, and cross-country harmonisation to confirm the measured concept is equivalent to the original.
How long does linguistic validation of a PRO questionnaire take?
It depends on the number of languages, the instrument's complexity and the copyright holder's availability to approve each stage; there is no fixed timeline, and each phase should be scoped and quoted separately.
Is cognitive debriefing mandatory for every study?
ISPOR guidelines recommend it as best practice for most PRO instruments used in EMA or FDA submissions, though the instrument's copyright holder may define exceptions depending on the type of scale.
